Swedish biotech holding Flerie AB trades at 50% NAV discount

Flerie AB is a Swedish listed investment company that concentrates on the biotech and healthcare sectors. It offers investors exposure to a diversified portfolio of biotech firms without the need to evaluate individual early‑stage companies directly. The company is quoted on the stock exchange, providing liquidity and transparency.

The share price is around 20 Swedish kronor, roughly a 50 % discount to its net asset value of about 39 kronor per share. The NAV includes roughly 10 % cash and a mix of early‑stage (about two‑thirds) and commercial‑growth (about one‑third) biotech companies. Portfolio holdings feature firms such as Lipum, Prokarium and listed entities like Xspray. Founder and majority shareholder Thomas Eldered, with a background in contract manufacturing for pharmaceuticals, leads the firm.

The discount reflects a broader downturn in biotech valuations, where many innovative companies face financing challenges and valuation corrections. Investors view the discount as a potential entry point, with upside possible if individual portfolio companies achieve exits or valuation upgrades.